Myovant Sciences Ltd. reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported revenue was USD 100.23 million compared to USD 54.44 million a year ago. Net loss was USD 57.63 million compared to USD 63.45 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.68 a year ago.
For the nine months, revenue was USD 321.55 million compared to USD 173.41 million a year ago. Net loss was USD 124.49 million compared to USD 146.7 million a year ago. Basic loss per share from continuing operations was USD 1.29 compared to USD 1.59 a year ago.